ASCO 2023

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

Ribociclib has arrived in the adjuvant setting

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

Another proof of efficacy of immunotherapy in advanced TNBC

TILs are prognostic but not predictive in HER2+ EBC

Young patients benefit from ovarian suppression

Can we preserve our patients form chemotherapy?

TILs in HER2+ disease - prognostic, but not enough to deescalate

De-escalation of CT for early BC

Early follow-up shows clear benefit

Ribociclib improves iDFS

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

1/3 of patients with HER2+ in future without chemotherapy?

My EBC highlights from ASCO23

Discussions on CDK4/6 inhibitors in EBC

More CDK4/6 options for EBC patients

A challenge for clinical management

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

Practice changing or not quite yet?

10 years update on ShortHER

Ovarian function - Ovarian suppression not necessary in young patients?

First data with adjuvant ribociclib

From PENELOPE-B to SURVIVE

Palbociclib after Palbociclib might not be the best option

SOC of ovarian ablation confirmed in meta-analysis.

Response adapted, chemotherapy-free option in HER2+ EBC

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

NATALEE nicht überraschend aber überzeugend positiv

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

I miei punti salienti di ASCO23

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

SOC der ovarialen Ablation in der Metaanalyse bestätigt

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

Eine Herausforderung für das klinische Management

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

Primele date cu ribociclib adjuvant

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

Von PENELOPE-B zur SURVIVE

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

Palbociclib después de Palbociclib podría no ser la mejor opción

Eine Herausforderung für viele Patienten, wenig Doktoren

Czy wystarczy, aby zmienić standardy?

Molecular imaging for endocrine responsivness

The start of precision medicine in HR+ breast cancer

What is the optimal therapie sequence for HR+ MBC patients?

Updates on ADCs in metastatic breast cancer

E-Health Applications in Oral Cancer Therapy

Continued OS benefit for Sacituzumab Govitecan

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

Mises à jour sur les ADC dans le cancer du sein métastatique

The value of eHealth

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

Update ADC efficacy

CDK4/6i in first line and beyond & Biomarkers

PEACE 1 - results and controversies

Metastasis-directed for prostate cancer

PRL-02: Intramuscular arbiraterone

LuPARP combination study: LuPSMA and Olaparib in mCRPC

Confirming results for PARPi in mCRPC

Intensified or de-intensified therapy in mHSPC

ARASEC: ADT + Daralutamide for mHSPC

Part2: Important update on testosterone-recovery

Reassuring real-world data!

DEAR trial: real-world comparator analyses of ARIs

AI for prediction in local prostate carcinoma

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

TALAPRO-2: Results and controversies

Part 1: Important update on testosterone-recovery

PAPR-inhibitors: Patient-selection matters!

Over-staging of bone scan compared with PSMA PET/CT

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

Intensifierad eller de-intensifierad behandling vid mHSPC?

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

PARP-inhibitors: La selección de pacientes es importante

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

What is your preferred sequence in 1st line treatment and how you treat after progress?

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

The beginning of a new era in urothelial cancer?!

Q-TWiST in the therapy of aUC

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

Targeted therapies in advanced urothelial cancer: The renaissance?!

New standard for MIBC

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

New SoC option for metastatic bladder cancer

Extent of lymphadenectomy in cystectomy

FGFR inhibition

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Nouvelles options de soins standard pour le cancer de la vessie métastatique

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

The efficacy of FGFR targeting

Update EV/Pembro, Avelumab Maintenance

Primary endpoint not reached: what do we learn from CONTACT-03 results?

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

Non ccRCC: how should we treat patients today?

The impact of microbiome and supplements on therapy efficacy

Update and take home message of 1st Line mRCC

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

Long-term follow-up for IO/TKI in mRCC

IO rechallenge in mRCC

New standard for 2nd line RCC?

New data non ccRCC

News from the adjuvant

1st Line therapy RCC: which combination to choose?

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

Adjuvant and neoadjuvant strategies in resectable NSCLC

A new standard of care

EGFR testing necessary in the adjuvant setting

Induction options in the perioperative setting

Adjuvant IO in KRASm patients

ADAURA - Discussion closed?

CheckMate 9LA: 4‑year clinical update

ADAURA - results and controversies

An imperfect analysis, but perfect results

Perioperative treatment

Role of periopertative IO confirmed

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

A chemo-free preop. IO strategy?

More options in the perioperative setting

A new standard of care for operated patients with eGFRmut adenocarcinoma

OS benefit from EGFR receptor TKI

Confirmation of neoadjuvant immunotherapy

Another neoadjuvant chemo/IO option

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

Rolle der periopertativen IO bestätigt

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Más opciones en el entorno perioperatorio

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

ADAURA- discussie gesloten?

Sotorasib: clear clinical benefit, but short follow-up time

Zorifertinib: an option when osimertinib is not available

Does ADC + chemo + IO replace the existing concepts?

TTF-treatment requires further studies

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

Update on KRASG12Cm treatment options - how to proceed?

IO in EGRF positive patients post TKI

ADC + ICI ± Pt-CT in patients with aNSCLC

LUNAR: TTF medical device shows OS-benefit, but more information needed

Stopping treatment is ok

CORRELATE - a real world analysis

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

More BiTEs, more possibilities

Can we incoporate biomarkers in SCLC treatment?

Hyperfractionated radiotherapy for SCLC

A positive trial with no impact

Treatment strategies in SCLC

Stratégies de traitement dans le SCLC

Más BiTEs, más posibilidades

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

No practice-changing data in mesothelioma, other studies to await

Immune checkpoint inhibitors in malignant mesothelioma

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom